Search Results for 'Clinical Pfs'

Where we are with targeted

• stefany-barnette
• 32 Slides

therapies . for . cholangiocarcinoma. Professor J...

State of the Art in BRCA

• ellena-manuel
• 0 Slides

-Mutated Ovarian Cancer. This program will includ...

Case Discussion: Second

• celsa-spraggs
• 0 Slides

Opinion. 55 year-old woman with . recurrent . ova...

Exemplary Practices and Your

• olivia-moreira
• 0 Slides

Evaluation. . Report. Migrant Education Program ...

Common Knee Injuries Meniscus Tears

• celsa-spraggs
• 0 Slides

Knee twisted suddenly. One or both menisci become...

EGFR-Mutated Advanced NSCLC

• sherrill-nordquist
• 0 Slides

The Coming Paradigm Shift. Faculty. Suresh S. Ram...

Emanuele Zucca, MD Oncology Institute of Southern Switzerland (IOSI)

• ellena-manuel
• 0 Slides

Swiss Group for Clinical Cancer Research (SAKK). ...

Raising the Bar in the Management of Advanced/Metastatic NSCLC

• debby-jeon
• 0 Slides

Dr Tan . Jiunn. Liang. Clinical Specialist (Resp...

Indolent Non-Hodgkin L

• danika-pritchard
• 0 Slides

ymphoma. Sobia Ozair. March 8, 2017. MD Anderson ...

A1 Using a Positive Family Support Screener to Inform Tiered Supports

• natalia-silvester
• 0 Slides

Strand:. Applied Evaluation. Recommended Experie...

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

• ellena-manuel
• 0 Slides

Program Overview . Discussion Outline. DNA Repair...

Pharmacist Focus on BTK Inhibitors Moderator Shilpa Paul, PharmD, BCOP

• ellena-manuel
• 25 Slides

Pharmacist Focus on BTK Inhibitors Moderator Shil...

The Impending D eath of Cancer: A Herculean Task Emerging Therapies 2016

• phoebe-click
• 33 Slides

The Impending D eath of Cancer: A Herculean Task...

Targeting endocrine-resistance pathways in breast cancer

• alexa-scheidler
• 48 Slides

Targeting endocrine-resistance pathways in breas...

Overall Survival Benefit of

• tatyana-admore
• 123 Slides

Obinutuzumab. Over Rituximab when Combined with ...

NEw developments IN gynecological Oncology

• cheryl-pisano
• 211 Slides

highlights from the. EUROPEAN . society . of med...

Ovarian cancer with update from ASCO 2013

• karlyn-bohler
• 39 Slides

Siew. . wei. . wong. Oncology registrar. Epidem...

Romidepsin in Association with CHOP in Patients with Peripheral T

• accompanypepsi
• 13 Slides

-Cell . Lymphoma: Final Results of the Phase . Ib....

Endocrine resistance: molecular pathways and rational development of targeted therapies

• spottletoefacebook
• 66 Slides

Grazia Arpino. Università di Napoli Federico II. ...

Behandeling van het recidief ovariumcarcinoom

• sandsomber
• 18 Slides

Ignace Vergote MD PhD FACS FSPS. Chairman, Leuven ...

ASCO 2012 Review Gynecologic Cancer

• welnews
• 66 Slides

Nelson Teng, M.D., Ph.D.. Director, Gynecologic On...

Please note, these are the actual video-recorded

• chaptoe
• 71 Slides

proceedings from the live CME event and may includ...

Please note, these are the actual video-recorded

• blindnessinfluenced
• 27 Slides

proceedings from the live CME event and may includ...

Please note, these are the

• markes
• 20 Slides

actual. . video-recorded proceedings from the . l...

End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC

• maniakti
• 43 Slides

Richard S. Finn, MD. Professor of Clinical Medicin...

• billiontins
• 108 Slides

2018;36(8):773-9.. Nivolumab Monotherapy (Cohort 1...

Colorectal Cancer in Older

• stingraycartier
• 58 Slides

Patients. Key Issues. Etienne GC . Brain. , MD . P...

MRD = Minimal Resistant Disease?

• shoffer
• 23 Slides

Roger Owen. St James’s Institute of Oncology. Le...

Ovarian Cancer: Standards of Care and New Opportunities

• majerepr
• 63 Slides

Robert L. Coleman, M.D.. Professor & . Vice Ch...

Sizing the

• callie
• 1 Slides

TAFO : 1. Fit it. Measure for an accurate size . ...

x0000x0000 xMCIxD 0 xMCIxD 0 xMCIxD 1 x

• wang
• 8 Slides

�� &#x/MCI; 1 ;&#x/MCI; 1 ;...

Alumbrera

• tremblay
• 17 Slides

669790 MARA Project Agua Rica – Asset Overvie...

Advances in Systemic Amyloidosis:

• morton
• 62 Slides

A Spotlight on New Disease-Modifying . Therapies A...

CDK4-6 INHIBITORS IN Breast Cancer: Optimal Treatment Sequencing

• leah
• 28 Slides

Mansoor A Khan, BS, MS, BCOP. Oncology/Hematology/...

Updates on T-cell lymphoma

• grace3
• 18 Slides

Dr. Stefan K. Barta. University of Pennsylvania, U...

Efficacy of sorafenib in patients with

• caitlin
• 1 Slides

desmoid. -type . fibromatosis. Rodrigo Munhoz. 1. ...

iJOURNAL CLUB: Optimizing Therapy for Patients with Metastatic Squamous Cell Carcinoma of the Lung

• berey
• 45 Slides

Interview with Shirish M . Gadgeel. , MD . January...

The Impending D eath of Cancer:

• elina
• 33 Slides

A Herculean Task. Emerging Therapies 2016. Ruemu E...

First Prospective Data on Minimal Residual Disease (MRD) Outcomes After Fixed-Duration Ibrutinib P

• mia
• 23 Slides

Ibr+Ven. ) Versus Chlorambucil Plus Obinutuzumab (...

Impact of Imatinib interruption & duration of prior Hydroxyurea on treatment outcome in CML pat

• hadly
• 17 Slides

Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof C...